Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine

Hepatology Research

Volumn 41, Issue 5, 2011, Pages 405-416

  Kobashi, Haruhiko ^a   Miyake, Yasuhiro ^a   Ikeda, Fusao ^a   Yasunaka, Tetsuya ^a   Nishino, Ken ^b   Moriya, Akio ^b   Kubota, Jyunichi ^c   Nakamura, Shinichiro ^a   Takaki, Akinobu ^a   Nouso, Kazuhiro ^a   Yamada, Gotaro ^b   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c Tsuyama Central Hospital   (Japan)

Author keywords

fetoprotein; Chronic hepatitis B; Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD TESTIS BARRIER; CANCER DIAGNOSIS; CANCER INCIDENCE; CHRONIC HEPATITIS; CHRONIC PATIENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY;

EID: 79955161000     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00785.x     Document Type: Article

References (47)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Merican I, Guan R, Amarapuka D etal. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356-61.
3. Liaw YF, Tai DI, Chu CM, Chen TJ. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-41.
4. Wands JR. Prevention of hepatocellular carcinoma. N Engl J Med 2004; 351: 1567-70.
5. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
6. Nishida T, Kobashi H, Fujioka S etal. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 2008; 23: 794-803.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
8. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
9. Kobashi H, Takaguchi K, Ikeda H etal. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: Phase II clinical study in Japan. J Gastroenterol Hepatol 2009; 24: 262-9.
10. Yokosuka O, Takaguchi K, Fujioka S etal. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010; 52: 791-9.
11. Karino Y, Toyota J, Kumada H etal. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 2009; 3: 403-10.
12. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
13. Matsumoto A, Tanaka E, Rokuhara A etal. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
14. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across abiological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
15. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
16. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
17. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
18. Keeffe EB, Dieterich DT, Han SH etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-41.
19. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Third English edition. Tokyo: Kanehara & Co.Ltd, 2010.
20. Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39: S50-8.
21. Chan HL, Hui AY, Wong ML etal. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-8.
22. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-34.
23. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-54.
24. Yuen MF, Yuan HJ, Wong DK etal. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-14.
25. Zhang H, Zhai Y, Hu Z etal. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-8.
26. Lok ASF. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastrpenterology 2004; 127: S303-9.
27. Niederau C, Heintges T, Lange S etal. Long-term follow-up of HBeAg-positive patients treated with interferonalpha for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
28. Ikeda K, Saitoh S, Suzuki Y etal. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82: 827-35.
29. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
30. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
31. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
32. Makuuchi M, Kokudo N, Arii S etal. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
33. Taketa K. Alpha-fetoprotein:Reevaluation in hepatology. Hepatology 1990; 12: 1420-32.
34. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-8.
35. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
36. Kai I, Arii S, Okazaki M etal. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37; 676-91.
37. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-30.
38. Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alpha-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J Viral Hepat 2010; 17: 511-17.
39. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990; 11: 481-8.
40. Cui R, Wang B, Ding H, Shen H, Li Y, Chen X. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin Med J (Engl) 2002; 115: 42-5.
41. Nakamura S, Nouso K, Sakaguchi K etal. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-43.
42. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of consensus meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-85.
43. Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci 1999; 64: 17-23.
44. Li MS, Li PF, He SP, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol 2002; 8: 469-75.
45. Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol 2004; 10: 819-24.
46. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and betacatenin mutations. Int J Cancer 2004; 112: 44-50.
47. Zhou YM, Yang JM, Li B etal. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int 2010; 9: 33-7.